Close Asset Management Ltd Has $716,000 Position in Arcutis Biotherapeutics, Inc. $ARQT

Close Asset Management Ltd trimmed its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) by 41.3% in the third quarter, Holdings Channel.com reports. The firm owned 38,000 shares of the company’s stock after selling 26,774 shares during the quarter. Close Asset Management Ltd’s holdings in Arcutis Biotherapeutics were worth $716,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in ARQT. Johnson Investment Counsel Inc. bought a new stake in shares of Arcutis Biotherapeutics during the third quarter worth $30,000. PNC Financial Services Group Inc. boosted its holdings in shares of Arcutis Biotherapeutics by 10.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,828 shares of the company’s stock valued at $124,000 after acquiring an additional 820 shares in the last quarter. Jones Financial Companies Lllp grew its position in Arcutis Biotherapeutics by 1,291.1% during the 3rd quarter. Jones Financial Companies Lllp now owns 7,067 shares of the company’s stock worth $124,000 after acquiring an additional 6,559 shares during the last quarter. Atlas Wealth LLC acquired a new position in Arcutis Biotherapeutics in the 2nd quarter worth about $138,000. Finally, Quantbot Technologies LP acquired a new position in Arcutis Biotherapeutics in the 2nd quarter worth about $145,000.

More Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Reported a robust Q4: ZORYVE product revenue of $127.5M (+84% YoY) and full‑year ZORYVE sales of $372.1M (+123% YoY); company raised 2026 net product sales guidance to $480–$495M — a clear driver of upward momentum. Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Beat EPS and revenue estimates: Q4 GAAP EPS $0.13 vs. consensus $0.03 and revenue ~$129.5M vs. $110.8M expected — the earnings beat and recurring revenue growth support a re-rating. ARQT Earnings Report
• Positive Sentiment: Clinical and regulatory catalyst: positive topline data in a Phase 2 infant trial for ZORYVE with an sNDA submission expected in Q2 2026 — potential label expansion that could meaningfully grow addressable market. Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst upgrades: Needham raised its PT to $36 (buy) and TD Cowen raised its PT to $35 (buy), both implying >20% upside from current levels — these broker actions can drive buying interest. Needham Price Target Raise
• Positive Sentiment: Operational improvements: company produced positive operating cash flow in Q4 and expects to maintain positive operating cash flow quarterly going forward; also expanding dermatology sales and targeting primary care/pediatrics — supports sustainable commercialization. Business Update and Guidance
• Neutral Sentiment: Wall‑street commentary and analysis: bullish writeups (Seeking Alpha) highlight ZORYVE dominance and pipeline catalysts but note valuation is elevated (~9x forward EV/sales). Seeking Alpha Bull Case
• Neutral Sentiment: Marketing/awareness initiatives: consumer awareness campaign (celebrity partnership) may help demand over time but is not an immediate revenue driver. Marketing Campaign
• Neutral Sentiment: Short interest data reported is internally inconsistent (zeros/NaN) and provides no actionable signal. (Ignore until clearer filings are available.)
• Negative Sentiment: Profitability metrics remain mixed: company still showed negative net margin and negative ROE in some reports, and some analysts project a net loss (consensus -1.33 EPS for the year) — these fundamentals temper the upside and could limit multiple expansion if growth slows. ARQT Stock Summary

Insider Buying and Selling

In other Arcutis Biotherapeutics news, insider Patrick Burnett sold 11,500 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $28.94, for a total value of $332,810.00. Following the transaction, the insider directly owned 98,307 shares of the company’s stock, valued at approximately $2,845,004.58. The trade was a 10.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Todd Watanabe sold 19,833 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.50, for a total value of $505,741.50. Following the transaction, the insider owned 721,306 shares in the company, valued at $18,393,303. The trade was a 2.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 124,656 shares of company stock worth $3,312,365 over the last three months. Insiders own 9.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ARQT. HC Wainwright boosted their price target on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday. Needham & Company LLC boosted their target price on shares of Arcutis Biotherapeutics from $31.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday. Zacks Research cut shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Finally, Mizuho boosted their price objective on shares of Arcutis Biotherapeutics from $32.00 to $37.00 and gave the stock an “outperform” rating in a research note on Friday, November 28th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Arcutis Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $31.67.

Arcutis Biotherapeutics Stock Up 5.8%

Arcutis Biotherapeutics stock opened at $28.57 on Friday. The firm has a market cap of $3.50 billion, a price-to-earnings ratio of -204.06 and a beta of 1.70. Arcutis Biotherapeutics, Inc. has a 52-week low of $11.86 and a 52-week high of $31.77. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.28 and a current ratio of 3.50. The firm has a 50 day moving average price of $27.26 and a two-hundred day moving average price of $23.71.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.10. The company had revenue of $129.50 million during the quarter, compared to analysts’ expectations of $110.79 million. Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 11.01%. Equities analysts predict that Arcutis Biotherapeutics, Inc. will post -1.33 EPS for the current year.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.